Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Girish Badarke"'
Autor:
BJ Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, D Tousif, Raghavendra Rao, Amritanshu Ram, Shekar Patil, Radheshyam Naik
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 12 (2018)
Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of er
Externí odkaz:
https://doaj.org/article/17d9df9007f0458e8761743c698fc60d
Publikováno v:
South Asian Journal of Cancer, Vol 7, Iss 3, Pp 170-187 (2018)
South Asian Journal of Cancer
South Asian Journal of Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40b4c97b0d3794772f374e72f98b554
http://journal.sajc.org/article.asp?issn=2278-330X
http://journal.sajc.org/article.asp?issn=2278-330X
Autor:
G. S. Deepika, B. J. Srinivasa, Raghavendra M Rao, D. Tousif, Kiran Pk, Amritanshu Ram, Radheshyam Naik, Mohammad Nasiruddin, Sulav Sapkota, S. Patil, Girish Badarke, Vinu Sarathy, L. P. Bhanu, Vishal Kulkarni
Publikováno v:
Journal of Cancer Therapy. :838-844
Background: Lung cancer is the leading cause of cancer-related death worldwide with an estimated 1.6 million new cases diagnosed each year. According to standard guidelines in NSCLC, the effectiveness of combined chemotherapy regimen comprises of pem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4d99e0f3c159463931e479f21aff25
https://doi.org/10.4236/jct.2017.89073
https://doi.org/10.4236/jct.2017.89073
Autor:
Radheshyam Naik, Shivakumar Swamy, Girish Badarke, B. J. Srinivasa, Mona Priyadarshini, R. Veena ., Sulav Sapkota
Publikováno v:
Indian Journal of Case Reports. 4:295-297
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fc7169c5b164190526328425aba5d28
https://doi.org/10.32677/ijcr.2018.v04.i04.014
https://doi.org/10.32677/ijcr.2018.v04.i04.014
Autor:
Raghavendra M Rao, Mansi Khanderia, Bhanu Prakash Lalkota, Amritanshu Ram, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Girish Badarke, Radheshyam Naik, D. Tousif, Shekar Patil, B. J. Srinivasa
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 12 (2018)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights. Oncology
Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fabb719f40dceb8250f3258b0e1a40f
https://doaj.org/article/17d9df9007f0458e8761743c698fc60d
https://doaj.org/article/17d9df9007f0458e8761743c698fc60d